Through Fenwal, Fresenius Kabi also gets broader access to the U.S. transfusion technology market, Schneider further said.

Fenwal, which has about 4,900 employees and operates five manufacturing facilities, will be combined with Fresenius Kabi, which has more than 24,000 employees.

In 2011, Fenwal posted sales of $614 million with an adjusted earnings before interest taxes and amortization of $90 million. In 2011, Fresenius Kabi’s sales totaled 3.96 billion euros ($4.82 billion) and the company’s earnings before interest, taxes and amortization came in at 955 million euros.